Published in J Pept Sci on June 01, 2003
Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol (2006) 2.50
Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol (2003) 2.03
Histone deacetylase inhibitors: from bench to clinic. J Med Chem (2008) 1.79
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes (2009) 1.65
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55
Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis. Arthritis Rheum (2013) 1.44
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A (2010) 1.36
Chromatin remodeling by the SWI/SNF-like BAF complex and STAT4 activation synergistically induce IL-12Rbeta2 expression during human Th1 cell differentiation. EMBO J (2007) 1.36
Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A (2005) 1.36
RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1. J Biol Chem (2004) 1.35
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29
The COP9 signalosome regulates Skp2 levels and proliferation of human cells. J Biol Chem (2006) 1.25
Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog (2010) 1.25
Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood (2013) 1.16
Progress towards the development of a HIV-1 gp41-directed vaccine. Curr HIV Res (2004) 1.13
Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A (2004) 1.12
A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation. FASEB J (2009) 1.12
Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc Natl Acad Sci U S A (2004) 1.11
Viral entry inhibitors targeted to the membrane site of action. J Virol (2010) 1.10
Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol (2005) 1.07
Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem (2011) 1.06
Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein. J Virol (2011) 1.06
RanBPM associates with CD39 and modulates ecto-nucleotidase activity. Biochem J (2006) 1.05
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood (2006) 1.04
Protein minimization of the gp120 binding region of human CD4. Biochemistry (2005) 0.99
Genetic and epigenetic networks controlling T helper 1 cell differentiation. Immunology (2009) 0.98
Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain. FASEB J (2012) 0.98
Enhancement of transactivation activity of Rta of Epstein-Barr virus by RanBPM. J Mol Biol (2008) 0.98
COP9 signalosome subunit 5 (CSN5/Jab1) regulates the development of the Drosophila immune system: effects on Cactus, Dorsal and hematopoiesis. Genes Cells (2007) 0.97
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs (2009) 0.95
Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat (2009) 0.93
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial. Health Expect (2011) 0.93
Integration of distinct intracellular signaling pathways at distal regulatory elements directs T-bet expression in human CD4+ T cells. J Immunol (2009) 0.92
The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring) (2012) 0.90
Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses (2008) 0.89
Regulation of mu opioid receptor internalization by the scaffold protein RanBPM. Neurosci Lett (2009) 0.87
An intracellular role for the C1q-globular domain. Cell Signal (2006) 0.87
Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J Virol (2013) 0.87
Expression pattern of the JAB1/CSN5 gene during murine embryogenesis: colocalization with NEDD8. Gene Expr Patterns (2004) 0.86
COPS5 (Jab1) protein increases β site processing of amyloid precursor protein and amyloid β peptide generation by stabilizing RanBP9 protein levels. J Biol Chem (2013) 0.86
A functionally orthogonal estrogen receptor-based transcription switch specifically induced by a nonsteroid synthetic ligand. Chem Biol (2005) 0.86
RanBPM regulates the progression of neuronal precursors through M-phase at the surface of the neocortical ventricular zone. Dev Neurobiol (2010) 0.85
A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies. J Med Chem (2006) 0.85
DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci (2011) 0.84
hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett (2011) 0.83
Inhibiting viral proteases: challenges and opportunities. Biopolymers (2002) 0.83
PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes. Bioorg Med Chem (2012) 0.83
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide. J Pept Sci (2013) 0.81
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets. Electrophoresis (2009) 0.81
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. PLoS One (2012) 0.81
ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose. Bioorg Med Chem (2010) 0.81
Talking about end-of-life preferences with advanced cancer patients: factors influencing feasibility. J Pain Symptom Manage (2012) 0.80
A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorg Med Chem (2013) 0.80
Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action. J Virol (2011) 0.79
Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry (2002) 0.79
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure. J Antimicrob Chemother (2014) 0.79
RanBP9 Plays a Critical Role in Neonatal Brain Development in Mice. PLoS One (2013) 0.79
Synthetic peptide vaccines: the quest to develop peptide vaccines for influenza, HIV and Alzheimer's disease. Adv Exp Med Biol (2009) 0.79
Fragment-based drug design: combining philosophy with technology. Curr Opin Drug Discov Devel (2007) 0.78
The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure. Protein Sci (2002) 0.77
Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors. Bioorg Med Chem Lett (2011) 0.77
The human COP9 signalosome protects ubiquitin-conjugating enzyme 3 (UBC3/Cdc34) from beta-transducin repeat-containing protein (betaTrCP)-mediated degradation. J Biol Chem (2010) 0.77
Dynamic regulation of the COP9 signalosome in response to DNA damage. Mol Cell Biol (2014) 0.77
Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-beta particle formation in vitro. Bioorg Med Chem Lett (2009) 0.75
A strategy for selectively shielding portions of a peptide/protein from immune response while maintaining immunogenicity of contiguous epitopes. Adv Exp Med Biol (2009) 0.75
Editorial: peptide-based strategies for protease inhibition. Biopolymers (2002) 0.75
A practical approach to the synthesis of hairpin polyamide-peptide conjugates through the use of a safety-catch linker. Bioorg Med Chem Lett (2002) 0.75
A peptide vaccine based on retro-inverso beta-amyloid sequences fails to elicit a cross-reactive immune response. Adv Exp Med Biol (2009) 0.75